Ask AI
ProCE Banner Activity

Setting New Standards With TROP2-Directed Therapy in NSCLC: Leveraging ADC Innovation to Meet Unmet Patient Needs

Slideset

Download this slideset on the current and emerging use of TROP2-directed antibody–drug conjugates in the management of patients with advanced NSCLC, including the latest evidence on use in different disease settings, emerging biomarkers for potential selection of patients, and practical insights on toxicity management.

Released: January 28, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the significance of TROP2 expression in NSCLC and the therapeutic rationale for targeting TROP2 with antibody–drug conjugates

  • Compare and contrast potential indications, efficacy, and toxicity profiles among available and investigational agents targeting TROP2 in NSCLC

  • Analyze and integrate TROP2 ADCs for patients with NSCLC based on a comprehensive understanding of available clinical data and expert recommendations

  • Design a tailored supportive care plan to manage treatment-related AEs in patients receiving TROP2–targeted therapy, emphasizing QoL and patient comfort